Icosapent ethyl reduces coronary revascularization by 11 months: REDUCE-IT REVASC
Click Here to Manage Email Alerts
Icosapent ethyl demonstrated a very early coronary revascularization benefit, according to findings from REDUCE-IT REVASC.
The data, presented at the virtual American Society for Preventive Cardiology Congress on CVD Prevention, determined that the benefit in patients assigned icosapent ethyl (Vascepa, Amarin) met statistical significance by 11 months.
“These data highlight the early and substantial impact of icosapent ethyl on the atherothrombotic burden in the at-risk REDUCE-IT population,” Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today intervention section editor, said during the presentation.
“Revascularization procedures significantly impact the health care system,” Steven Ketchum, PhD, senior vice president, president of research and development and chief scientific officer of Amarin, said in a press release from the company. “These data reflect results consistent with FDA-approved findings that continue to support that the use of Vascepa has the potential to transform cardiovascular care in appropriate high-risk patients.”
Some data presented at ASPC were also presented at the virtual Society for Cardiovascular Angiography and Interventions Scientific Sessions in May. As Healio previously reported, a prespecified analysis of the REDUCE-IT trial highlighted a reduction in first and total revascularization events with icosapent ethyl in patients with elevated triglycerides at high CV risk despite statin therapy. Treatment with icosapent ethyl 4 g per day, compared with matching placebo, significantly reduced first revascularization events by 34% (HR = 0.66; 95% CI, 0.58-0.76) and total revascularization events by 36% (RR = 0.64; 95% CI, 0.56-0.74) during a mean follow-up of 5.7 years.
Other data presented at ASPC and SCAI include:
- a 32% reduction in time to elective coronary revascularization with icosapent ethyl vs. placebo (HR = 0.68; 95% CI, 0.57-0.82);
- a 38% reduction in time to emergent coronary revascularization with icosapent ethyl vs placebo (HR = 0.62; 95% CI, 0.42-0.92); and
- a 34% reduction in time to urgent coronary revascularization with icosapent ethyl vs. placebo (HR = 0.66; 95% CI, 0.54-0.79).
There were 258 fewer cases of coronary revascularization overall in the icosapent ethyl group, according to Bhatt.
Need for PCI was reduced by 32% (HR = 0.68; 95% CI, 0.59-0.79) and need for CABG was reduced by 39% (HR = 0.61; 95% CI, 0.45-0.81) during follow-up among patients assigned icosapent ethyl compared with placebo.
“We report one of the largest reductions in coronary revascularization in a clinical trial,” Bhatt said during his ASPC presentation. “Comparison of relative risk reductions in revascularization in major clinical trials show that these results from REDUCE-IT exceed those that have come since the 4S trial.”
Collapse
Bhatt DL. Abstract #106. Presented at: American Society for Preventive Cardiology Congress on CVD Prevention; July 25-26, 2020 (virtual).
Click Here to Manage Email Alerts